Optimizing atoh1-induced vestibular hair cell regeneration

Laryngoscope

Volumn 124, Issue S5, 2014, Pages S1-S12

  Staecker, Hinrich ^a   Schlecker, Christina ^a   Kraft, Shannon ^a   Praetorius, Mark ^c   Hsu, Chi ^b   Brough, Douglas E ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b GENVEC INC   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adenovector; Atoh1; Balance; Hair cell regeneration; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; LUCIFERASE; ATOH1 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

ADULT; ANIMAL TISSUE; ARTICLE; ATOH1 GENE; BINDING AFFINITY; BODY EQUILIBRIUM; CELL REGENERATION; DNA VECTOR; GENE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HAIR CELL; HEARING; HUMAN; HUMAN TISSUE; INNER EAR; MOUSE; NONHUMAN; RETINA MACULA LUTEA; TISSUE CULTURE; VESTIBULAR DISORDER; VESTIBULAR HAIR CELL; ADMINISTRATION AND DOSAGE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; REGENERATION;

ANALYSIS OF VARIANCE; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HAIR CELLS, VESTIBULAR; HUMANS; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; POSTURAL BALANCE; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; REGENERATION;

EID: 84907691413     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24775     Document Type: Article

References (35)

1. Ryals BM, Rubel EW. Hair cell regeneration after acoustic trauma in adult Coturnix quail. Science 1988;240:1774-1776.
2. Bermingham NA, et al. Math1: an essential gene for the generation of inner ear hair cells. Science 1999;284:1837-1841.
3. Staecker H, et al. Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer. Otol Neurotol 2007;28:223-231.
4. Staecker H, Praetorius M, Brough D.E. Development of gene therapy for inner ear disease: using bilateral vestibular hypofunction as a vehicle for translational research. Hear Res 2011;276:44-51.
5. Izumikawa M, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 200511:271-276.
6. Kawamoto K, et al. Math1 gene transfer generates new cochlear hair cells in mature guinea pigs in vivo. J Neurosci 2003;23:4395-4400.
7. Weiss MA, et al. Viral-mediated gene transfer in the cochlea. Int J Dev Neurosci 1997;15: 577-583.
8. Dechecchi MC, et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001;75:8772-8780.
9. Einfeld DA, Roelvink PW. Advances towards targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther 2002;4:444-451.
10. Izumikawa M, et al. Response of the flat cochlear epithelium to forced expression of Atoh1. Hear Res 2008;240:52-56.
11. Praetorius M, et al. Adenovector-mediated hair cell regeneration is affected by promoter type. Acta Otolaryngol 2010;130:215-222.
12. Praetorius M, et al. Adenoviral vectors for improved gene delivery to the inner ear. Hear Res 2009;248:31-38.
13. Akiyama M, et al. Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 2004;9:218-230.
14. Einfeld DA, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001;75:11284-11291.
15. McVey D, et al. Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector. Mol Ther 2008;16:1444-1449.
16. Schlecker C, et al. Selective atonal gene delivery improves balance function in a mouse model of vestibular disease. Gene Ther 2011;18:884-890.
17. Staecker H, et al. Drug delivery to the inner ear using gene therapy. Otolaryngol Clin North Am 2004;37:1091-1108.
18. Kawamoto K, et al. The functional and structural outcome of inner ear gene transfer via the vestibular and cochlear fluids in mice. Mol Ther 2001;4:575-585.
19. Praetorius M, et al. Hearing preservation after inner ear gene therapy: the effect of vector and surgical approach. ORL J Otorhinolaryngol Relat Spec 2003;65:211-214.
20. Stover T, Yagi M, Raphael Y. Transduction of the contralateral ear after adenovirus-mediated cochlear gene transfer. Gene Ther 2000; 7:377-383.
21. Kho ST, et al. Safety of adeno-associated virus as cochlear gene transfer vector: analysis of distant spread beyond injected cochleae. Mol Ther 2000;2:368-373.
22. Plontke SK, Salt AN. Quantitative interpretation of corticosteroid pharmacokinetics in inner fluids using computer simulations. Hear Res 2003;182:34-42.
23. Vogels R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003;77:8263-8271.
24. Nwanegbo E, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004;11:351-357.
25. Gahery-Segard H, et al. Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 1997;27:653-659.
26. Gahery-Segard H, et al. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 1997;100:2218-2226.
27. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 1992;73:1429-1435.
28. Kidd AH, Banatvala JE, de Jong JC. Antibodies to fastidious faecal adenoviruses (species 40 and 41) in sera from children. J Med Virol 1983;11:333-341.
29. Shinozaki T, et al. Antibody response to enteric adenovirus types 40 and 41 in sera from people in various age groups. J Clin Microbiol 1987;25:1679-1682.
30. Sakurai F. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biol Pharm Bull 2008;31:1819-1825.
31. Liszewski MK, et al. Emerging roles and new functions of CD46. Springer Semin Immunopathol 2005;27:345-358.
32. Schnorr JJ, et al. Measles virus-induced down-regulation of CD46 is associated with enhanced sensitivity to complement-mediated lysis of infected cells. Eur J Immunol 1995;25:976-984.
33. Venail F, et al. Coxsackie adenovirus receptor and alpha nu beta3/alpha nu beta5 integrins in adenovirus gene transfer of rat cochlea. Gene Ther 2007;14:30-37.
34. Campochiaro PA, et al. Adenoviral vector-delivered pigment epitheliumderived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-176.
35. Morral N, et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997;8:1275-1286.